Tombolini, Beatrice
Borrelli, Enrico
Sacconi, Riccardo
Bandello, Francesco
Querques, Giuseppe http://orcid.org/0000-0002-3292-9581
Article History
Received: 11 October 2021
Accepted: 20 December 2021
First Online: 8 February 2022
Declarations
:
: The authors declare that there are no conflicts of interest regarding the publication of this article. Beatrice Tombolini: none. Enrico Borrelli: consultant for Zeiss (Dublin, USA), CenterVue (Padua, Italy). Riccardo Sacconi: consultant for Bayer Shering-Pharma (Berlin, Germany), Novartis (Basel, Switzerland), Zeiss (Dublin, USA). Francesco Bandello consultant for: Alcon (Fort Worth,Texas, USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee,Belgium), Zeiss (Dublin, USA). Giuseppe Querques consultant for: Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Bayer Shering-Pharma (Berlin, Germany), Heidelberg (Germany), Novartis (Basel, Switzerland), Sandoz (Berlin, Germany), Zeiss (Dublin, USA).
: This article does not contain any studies involving human participants performed by any of the authors.
: For this type of article a formal consent is not required.